North Chicago, Ill. – October 02, 2026 -- Saros Therapeutics has received its second Phase II award from the National Cancer Institute, worth approximately $2 million, to advance a nanoparticle-based cancer immunotherapy toward human clinical testing.

Washington – October 02, 2026 -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is presenting three new data sets on its monoclonal antibody imsidolimab at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Vienna, Austria, running September 30 through October 3, 2026.

Ashland, Missouri – October 02, 2026 -- ABK Biomedical Inc. has launched construction of a commercial-scale manufacturing facility at Cartwright Business Park in Ashland, Missouri, designed to produce its Eye90 microspheres for liver cancer treatment. The groundbreaking, attended by Missouri Governor Mike Kehoe, follows the company's April announcement selecting Ashland for its long-term U.S. manufacturing base.

South San Francisco, Calif. – October 02, 2026 -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) has granted 35,275 restricted stock units to 18 non-executive employees under its Inducement Plan.

Rigel ties new hire equity to four-year vesting schedule

The restricted stock units vest over four years, with 25% of each grant releasing annually. The Compensation Committee of Rigel's Board of Directors approved the awards as an inducement material to new employees joining the company.

Cambridge, Mass. – October 02, 2026 -- Marengo Therapeutics will present interim results from its STARt-002 trial combining invikafusp alfa with Gilead's TRODELVY (sacituzumab govitecan-hziy) at the Society for Immunotherapy of Cancer's 41st Annual Meeting in Phoenix, Arizona, November 4-8, 2026.

Nottingham, England – October 02, 2026 -- Quotient Sciences and Copenhagen-based Acesion Pharma have launched a collaboration to apply AI-enhanced formulation development to Acesion's early-stage pipeline of small molecules targeting atrial fibrillation, a condition affecting an estimated 50-60 million people globally.

Hong Kong – – October 02, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) presented preclinical data showing its ASC36_35FDC injectable combination drove a 24.8% body-weight reduction in a diet-induced obesity rat model on Day 14, outperforming two competitor co-formulations tested under identical dosing conditions.

The data were unveiled in a short oral discussion at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, held September 28–October 2, 2026, in Milan, Italy.

Valby – October 02, 2026 -- H. Lundbeck A/S will present late-breaking Phase III data on its multiple system atrophy (MSA) drug candidate amlenetug alongside new Parkinson's disease pipeline results at the International Congress of Parkinson's Disease and Movement Disorders (MDS) 2026 in Seoul, South Korea, running October 4-8.

London – October 02, 2026 -- Samfara has completed the acquisition of Chr. Olesen Synthesis, a Danish manufacturer of controlled-substance active pharmaceutical ingredients, marking the London-based life sciences investment firm's first deal. The transaction sees Samfara buy the business from Chr. Olesen and funds managed by Signet Healthcare Partners, with Chief Executive Thomas Moestrup co-investing alongside the new owner. Financial terms were not disclosed.

Suzhou – October 02, 2026 -- Novartis has agreed to pay Abogen Biosciences an upfront fee of USD 575 million to secure worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager for autoimmune diseases, with total deal value reaching up to approximately USD 7.2 billion if all milestones and options are exercised.